Abstract: The present invention provides a compound that has an inhibitory effect on DYRK and that is represented by general formula (I): wherein Q, R1, R2 and R3 are as defined in the description.

Abstract: An expanded particle producing apparatus includes a vessel and a blade stirrer that is located inside the vessel. The blade stirrer comprises a stirrer base and an impeller blade that is attached to the stirrer base. A distance from the bottom of the vessel to the center of the stirrer base (L1) and a depth of the vessel (L2) have a ratio (L1/L2) of 0.01 to 0.2. L1 is measured in a depth direction parallel to L2, and a central axis of the blade stirrer coincides with a central axis of the vessel. The apparatus is configured to produce expanded particles.

Abstract: Provided is a side rail 1 having an outer peripheral surface 14, an inner peripheral surface 13, a first axial side surface 11, and a second axial side surface 12 parallel to the first axial side surface 11, in which, a beveled portion 30 is provided between the outer peripheral surface 14 and the second axial side surface 12, the beveled portion 30 is formed in a tapered surface having a diameter gradually decreasing from the first axial side surface 11 toward the second axial side surface in an axial direction; a tapered surface 30a is provided between a first tapered surface portion 30a1 with an angle of 10° or more to the axial direction and a second tapered surface portion 30a2 provided between the first tapered surface portion 30a1 and the outer peripheral surface 14 and having a smaller angle of inclination to the axial direction than that of the first tapered surface portion.

Abstract: A method for producing expanded particles having a high expansion ratio by a pressure-release expansion with a simpler configuration and at a low facility cost is provided. A production device includes an expansion cylinder being provided with a connecting port that connects with open-system branch cylinder and having a space of a saturated steam atmosphere. The space of a saturated steam atmosphere may be a different space from a space inside the branch cylinder. A temperature (T1) inside the expansion chamber exceeds 102° C. and is not higher than a higher one of 108° C. and a temperature obtained by a melting point Tm of a thermoplastic resin minus 14° C. A temperature (T2) at a connecting port is not lower than 100° C., and the temperature (T1) is higher than the temperature (T2).

Abstract: Provided is a side rail 1 having an outer peripheral surface 14, an inner peripheral surface 13, a first axial side surface 11, and a second axial side surface 12 parallel to the first axial side surface 11, in which, a beveled portion 30 is provided between the outer peripheral surface 14 and the second axial side surface 12, the beveled portion 30 is formed in a tapered surface having a diameter gradually decreasing from the first axial side surface 11 toward the second axial side surface in an axial direction; a tapered surface 30a is provided between a first tapered surface portion 30a1 with an angle of 10° or more to the axial direction and a second tapered surface portion 30a2 provided between the first tapered surface portion 30a1 and the outer peripheral surface 14 and having a smaller angle of inclination to the axial direction than that of the first tapered surface portion.

Abstract: An expanded particle producing apparatus includes a vessel and a blade stirrer that is located inside the vessel. The blade stirrer comprises a stirrer base and an impeller blade that is attached to the stirrer base. A distance from the bottom of the vessel to the center of the stirrer base (L1) and a depth of the vessel (L2) have a ratio (L1/L2) of 0.01 to 0.2. L1 is measured in a depth direction parallel to L2, and a central axis of the blade stirrer coincides with a central axis of the vessel. The apparatus is configured to produce expanded particles.

Abstract: The present invention relates to novel compounds of a formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions comprising them and their use in therapy, for example as modulators of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR-1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.

Abstract: The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example as modulators of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.

Abstract: The present invention relates to novel compounds of a formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions comprising them and their use in therapy, for example as modulators of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR-1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.

Abstract: The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example as modulators of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSRla receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.

Abstract: The present invention provides a pharmaceutical composition which prevents from decreasing the blood exposure of the third generation coxib-drugs, a process for preparing the said pharmaceutical composition and its use. It has been founded in this invention that adding a basic amine or a basic amino acid, or a cyclodextrin to the third generation coxib-drug can afford a pharmaceutical composition which can prevent from decreasing the blood exposure, AUC and bioavailability. The pharmaceutical composition of the present invention has also good stability, which is useful for drugs. Namely, the technological thought that adding a basic amine or a basic amino acid, or a cyclodextrin to the third generation coxib-drug can prevent from decreasing the blood exposure, AUC and bioavailability has been established in this invention.

Abstract: This invention relates to salts and crystal forms of (S)-6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid, Compound A, which is cyclooxygenase-2 inhibitor. The present invention provides a salt of compound A, a crystal form thereof, a process for preparing the said salt and a pharmaceutical composition thereof and its use. The salts and/or co-crystals of Compound A of the present invention show good formulation properties such as high aqueous solubility, good intrinsic dissolution, good crystallinity, good thermal stability or low hygroscopicity.

Abstract: This invention relates to salts and crystal forms of (S)-6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid, Compound A, which is cyclooxygenase-2 inhibitor. The present invention provides a salt of compound A, a crystal form thereof, a process for preparing the said salt and a pharmaceutical composition thereof and its use. The salts and/or co-crystals of Compound A of the present invention show good formulation properties such as high aqueous solubility, good intrinsic dissolution, good crystallinity, good thermal stability or low hygroscopicity.

Abstract: The present invention provides a pharmaceutical composition which prevents from decreasing the blood exposure of the third generation coxib-drugs, a process for preparing the said pharmaceutical composition and its use. It has been founded in this invention that adding a basic amine or a basic amino acid, or a cyclodextrin to the third generation coxib-drug can afford a pharmaceutical composition which can prevent from decreasing the blood exposure, AUC and bioavailability. The pharmaceutical composition of the present invention has also good stability, which is useful for drugs. Namely, the technological thought that adding a basic amine or a basic amino acid, or a cyclodextrin to the third generation coxib-drug can prevent from decreasing the blood exposure, AUC and bioavailability has been established in this invention.

Abstract: The present invention relates to novel oxyindole derivatives of formula (I) or a pharmaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the motilin receptor (GPR38).

Abstract: This invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, R5, R6, R7, k, m, n, p, q, r and s are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 receptor activity.

Abstract: The present invention relates to novel oxyindole derivatives of formula (I) or a pharmaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the motilin receptor (GPR38).

Abstract: This invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, R5, R6, R7, k, m, n, p, q, r and s are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 receptor activity.

Abstract: A food waste disposer includes a food conveying section, a grinding mechanism, and a brushless permanent magnet motor operably connected to the grinding mechanism. A discharge device is configured so as to reduce the overall height of the food waste disposer.

Abstract: A food waste disposer includes a food conveying section, a grinding mechanism, and a brushless permanent magnet motor operably connected to the grinding mechanism. A discharge device is configured so as to reduce the overall height of the food waste disposer.